Results 101 to 110 of about 12,533 (181)

Integrating Pharmacotherapy and Psychotherapy for Paediatric Bipolar Disorder: Translating Science to Service [PDF]

open access: yes, 2005
Objective: For comprehensive management of paediatric bipolar disorder (PBD), it is imperative to combine psychopharmacotherapy with specific psychotherapy.
Mani N., Pavuluri, Smita, Kampani
core  

Olanzapine / fluoxetine combination for treatment resistant depression : efficacy and clinical utility

open access: yes, 2008
Antidepressant monotherapy is a first-line treatment for depression; however, not all sufferers will adequately respond to treatment. When treating a patient with treatment-resistant depression, the clinician needs to consider all factors which may ...
Beasley   +47 more
core   +1 more source

Replacement of antipsychotics as a method of preventing the formation of resistance in schizophrenia

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
The article is devoted to the methods of overcoming therapeutic resistance in patients with schizophrenia, in particular, during the replacement of antipsychotic therapy.
G. E. Mazo, L. N. Gorobets
doaj  

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study

open access: yesEndocrine Regulations, 2018
Objective. The aim of the present study was to find out whether acute effect of different doses of selected antipsychotics including aripiprazole (ARI), amisulpride (AMI), asenapine (ASE), haloperidol (HAL), clozapine (CLO), risperidone (RIS), quetiapine
Kiss Alexander
doaj   +1 more source

NEW GENERATION VS. FIRST GENERATION ANTIPSYCHOTICS DEBATE: PRAGMATIC CLINICAL TRIALS AND PRACTICE-BASED EVIDENCE [PDF]

open access: yes, 2009
There has been significant confusion about the relative advantage of new generation antipsychotics over first generation antipsychotics as well as of clinical trials performed to evaluate their efficacy vs. those designed to evaluate their effectiveness.
Miro Jakovljević
core   +1 more source

Risk management of metabolic disorders in the use of antipsychotics

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018
Cardio-metabolic risk factors and diabetes mellitus type 2 are highly prevalent in patients with schizophrenia. Decrease of metabolic risks associated with use of atypical antipsychotics is connected with the development of specialised programs. They can
G. E. Mazo, A. O. Kibitov
doaj  

PREGNANCY AND ATYPICAL ANTIPSYCHOTICS [PDF]

open access: yes, 2009
Scientific research aiming at discovering new generations of effective medications is a common practice in medicine, and psychiatric research is no exception. Antipsychotics are used to treat chronic mental illnesses such as schizophrenia.
Daniela Petrić   +4 more
core   +1 more source

The effects of therapeutic concentrations of ziprasidone on free thiols and thiobarbituric acid reactive substances levels in human plasma – in vitro studies

open access: yesPsychiatria i Psychologia Kliniczna, 2012
The first and second generation antipsychotics may induce opposing effects on redox. Establishing the effects of antipsychotics on oxidative stress biomarkers is very important in clinical respect, because these drugs are used for the treatment of mental
Anna Dietrich-Muszalska   +3 more
doaj  

THE COMORBIDITY OF BIPOLAR DISORDER AND CARDIOVASCULAR DISEASES FROM PHARMACOTHERAPY PERSPECTIVE [PDF]

open access: yes, 2009
The heart and mind are intimately linked. Patients with severe mental disorders have increased mortality rates compared with the general population and the leading cause of premature death is cardiovascular disease (CVD).
Bjanka Vuksan–Ćusa   +3 more
core   +1 more source

Paciente con esquizofrenia tratado con ziprasidona + clozapina [PDF]

open access: yes, 2013
P es un paciente diagnosticado de esquizofrenia, sigue en un piso tutelado un programa de rehabilitación, está medicado con clozapina 500 mg/día y ziprasidona 280 mg/ día.
Pol Yanguas, Emilio
core   +1 more source

Home - About - Disclaimer - Privacy